Improving colorectal cancer screening with blood tests
Official title: SMARTER: Using Blood Samples to iMprove FIT-bAsed coloRecTal cancEr scReening
Run by Vejle Hospital · NCT06714318 · Data updated 2026-11-12
This study is testing whether blood tests can improve colorectal cancer screening for people aged 50-74 in Denmark by reducing unnecessary colonoscopies.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 50 Years to 74 Years |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Vejle Hospital Academic / other |
| Locations | 2 sites (Aabenraa and 1 other locations) |
| Status | Recruiting |
| Started | December 2, 2024 |
| Main results expected | May 2027 |
| Study ends | September 2028 |
| Registry record updated | June 29, 2026 |
| Trial ID | NCT06714318 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals aged 50-74 who are participating in the colorectal cancer screening program.
✕Probably not a fit
Patients who have not completed a colonoscopy or have a colorectal cancer obstruction may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project investigates the potential of using blood tests to enhance colorectal cancer screening, aiming to reduce unnecessary colonoscopies. Currently, individuals aged 50-74 in Denmark are invited to participate in a screening program that often leads to over a third of colonoscopies being unnecessary. By identifying blood biomarkers, the study seeks to determine individuals at very low risk of colorectal cancer after a positive stool test, thereby personalizing and optimizing the screening process. The goal is to alleviate the burden on healthcare resources while minimizing unpleasant procedures for patients.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the number of unnecessary colonoscopies for patients.
How similar studies have gone: While the approach of using blood tests for screening is innovative, similar studies have shown promise in enhancing screening accuracy and reducing unnecessary procedures.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participation in the colorectal cancer screening program. Exclusion Criteria: * Participants are excluded if a colonoscopy is not completed unless this is due to a colorectal cancer obstruction.
Where it's running
-
Hospital Sønderjylland
Aabenraa, Denmark Recruiting -
Vejle Hospital
Vejle, Denmark Recruiting
Study contacts
- Study coordinator: Line Fly, MD
- Email: line.haugaard.fly@rsyd.dk
- Phone: +4520367215
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Knife-assisted full-thickness resection for rectal lesions in a multicenter setting
A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.
-
Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery
Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.
-
Liver transplantation for colorectal cancer with liver metastases
This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.
-
LTZ-232: a first-in-human test in advanced colorectal and other solid tumors
A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.